纖溶酶原激活物抑制因子1(PAI1)真核蛋白
Eukaryotic Plasminogen Activator Inhibitor 1 (PAI1)
SERPINE1; PLANH1; Serpin Peptidase Inhibitor Clade E Member 1; Nexin,Plasminogen Activator Inhibitor Type 1 Serpin E1; Endothelial plasminogen activator inhibitor
- 編號(hào)EPA532Hu61
- 物種Homo sapiens (Human,人) 相同的名稱,不同的物種。
- 來源真核表達(dá)
- 宿主293F Cell
- 內(nèi)毒素水平<1.0EU/µg(LAL法測定)
- 亞細(xì)胞定位分泌
- 預(yù)測分子量44.4kDa
- 實(shí)際分子量46kDa(差異分析請(qǐng)參閱說明書)
- 片段與標(biāo)簽Val24~Pro402 with N-terminal His Tag
- 緩沖液成份PBS, pH7.4, containing 5% Trehalose.
- 性狀凍干粉
- 純度> 95%
- 等電點(diǎn)7.5
-
應(yīng)用
Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白,請(qǐng)參見活性蛋白。 - 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價(jià)格 ¥ 1368 ¥ 3420 ¥ 6840 ¥ 20520 ¥ 51300
- 欲了解實(shí)際交易價(jià)格和更多情況,請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
序列
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲(chǔ)存
避免反復(fù)凍融。2-8°C不超過一個(gè)月,-80°C不超過12個(gè)月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定,具體方法如下:在37°C孵育48小時(shí),沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲(chǔ),損失率低于5%。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
編號(hào) | 適用物種:Homo sapiens (Human,人) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPA532Hu02 | 纖溶酶原激活物抑制因子1(PAI1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
EPA532Hu61 | 纖溶酶原激活物抑制因子1(PAI1)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPA532Hu01 | 纖溶酶原激活物抑制因子1(PAI1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
APA532Hu61 | 纖溶酶原激活物抑制因子1(PAI1)活性蛋白 | Cell?culture;?Activity?Assays. |
PAA532Hu01 | 纖溶酶原激活物抑制因子1(PAI1)多克隆抗體 | WB; IHC; ICC; IP. |
PAA532Hu02 | 纖溶酶原激活物抑制因子1(PAI1)多克隆抗體 | WB; IHC; ICC; IP. |
LAA532Hu71 | 纖溶酶原激活物抑制因子1(PAI1)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
LAA532Hu81 | 纖溶酶原激活物抑制因子1(PAI1)多克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
MAA532Hu22 | 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | WB; IHC; ICC/IF |
MAA532Hu24 | 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | WB; IHC; ICC; IP. |
MAA532Hu27 | 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | WB; IHC; ICC; IP. |
MAA532Hu29 | 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | WB; IHC; ICC; IP. |
MAA532Hu25 | 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | WB; IHC; ICC; IP. |
MAA532Hu21 | 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | WB; IHC; ICC; IP. |
MAA532Hu26 | 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | WB; IHC; ICC; IP. |
MAA532Hu28 | 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | WB; IHC; ICC; IP. |
MAA532Hu23 | 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | WB; IHC |
FAA532Hu04 | 抗纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | Flow cytometry. |
FAA532Hu02 | 抗纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | Flow cytometry. |
FAA532Hu06 | 抗纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | Flow cytometry. |
FAA532Hu08 | 抗纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | Flow cytometry. |
LAA532Hu74 | 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
LAA532Hu76 | 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
MEA532Hu | 纖溶酶原激活物抑制因子1(PAI1)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,小樣本) | Enzyme-linked immunosorbent assay for Antigen Detection. |
SEA532Hu | 纖溶酶原激活物抑制因子1(PAI1)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
SCA532Hu | 纖溶酶原激活物抑制因子1(PAI1)檢測試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
LMA532Hu | 纖溶酶原激活物抑制因子1(PAI1)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
PSA532Hu01 | 纖溶酶原激活物抑制因子1(PAI1)抗體對(duì) | ELISA; CLIA; ELISPOT; Luminex; Immunochromatography and other Immunoassays. |
KSA532Hu01 | 纖溶酶原激活物抑制因子1(PAI1)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
Breast Cancer Research and Treatment | Oral administration of benzyl-isothiocyanate inhibits solid tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c mice [SpringerLink: f3w831267267p277] |
Clin Appl Thromb Hemost. | Is There Any Association Between Thrombosis and Tissue Factor Pathway Inhibitor Levels in Patients With Vitamin D Deficiency? [Pubmed: 24203351] |
Molecular Nutrition & Food Research | Trans‐fatty acid promotes thrombus formation in mice by aggravating antithrombogenic endothelial functions via Toll‐like receptors [PubMed: 25546502] |
Archives of Physiology and Biochemistry | Activation of cardiac renin–angiotensin system and plasminogen activator inhibitor-1 gene expressions in oral contraceptive-induced cardiometabolic disorder [Pubmed:26934364] |
Naunyn-Schmiedeberg's Archives of Pharmacology | Combined oral contraceptive-induced hypertension is accompanied by endothelial dysfunction and upregulated intrarenal angiotensin II type 1 receptor gene expression [pubmed:27447455] |
Environmental toxicology and pharmacology | Combined oral contraceptive and nitric oxide synthesis inhibition synergistically causes cardiac hypertrophy and exacerbates insulin resistance in female rats. [pubmed:28376377] |
Annals of Clinical & Laboratory Science | Alteration of Hemostatic Parameters in Patients with Different Levels of Subclinical Hypothyroidism and the Effect of L-thyroxine Treatment [pubmed:28249913] |
Pharmacological reports | Anti-inflammatory and antithrombotic effects of nicotine exposure in oral contraceptive-induced insulin resistance are glucocorticoid-independent [pubmed:28349880] |
Haematologica | Cytoprotective and pro-angiogenic functions of thrombomodulin are preserved in the C loop of the fifth epidermal growth factor-like domain [Pubmed:29903766] |
Biomedicine & Pharmacotherapy | Puerarin prevents vascular endothelial injury through suppression of NF-κB activation in LPS-challenged human umbilical vein endothelial cells [Pubmed:29775893] |
Archives of?Physical?Medicine?and Rehabilitation | Impact of Regular Physical Activity on Adipocytokines and Cardiovascular Characteristics in Spinal Cord–Injured Subjects [Pubmed:29548578] |
Marine Drugs | Anticoagulant and Antithrombotic Properties in Vitro and in Vivo of a Novel Sulfated Polysaccharide from Marine Green Alga Monostroma nitidum [Pubmed: 31027312] |
Experimental and Therapeutic Medicine | IKKβ regulates the expression of coagulation and fibrinolysis factors through the NF?κB canonical pathway in LPS?stimulated alveolar epithelial cells type II [Pubmed: 31572531] |
Phytomedicine | Sodium aescinate significantly suppress postoperative peritoneal adhesion by inhibiting the RhoA/ROCK signaling pathway [Pubmed: 32120245] |
Sci Rep | Fibroblast growth factor-21 as a novel metabolic factor for regulating thrombotic homeostasis [Pubmed:35013379] |
Phytomedicine | Multi-omics analysis reveals the mechanisms of action and therapeutic regimens of traditional Chinese medicine, Bufei Jianpi granules: Implication for COPD drug?… [Pubmed:35121390] |
留言咨詢